Summit Therapeutics partners with AstraZeneca, Daiichi Sankyo to test ivonescimab with Datroway in solid tumors
SMMT•Summit Therapeutics entered a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to test ivonescimab with Datroway in solid tumors. The companies plan to begin with a Phase III trial in first-line triple-negative breast cancer, with potential expansion into breast and lung cancer.
1. Planned clinical trials
The collaboration will start with a Phase III trial in first-line triple-negative breast cancer, with the companies targeting expansion into breast and lung cancer. AstraZeneca or Daiichi Sankyo will sponsor the studies, and all three companies will share trial costs.
2. Drug rights and supply
Each company will supply its own drug for the trials and retain development and commercial rights to its respective medicine.
